+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

Cerebral Amyloid Angiopathy - Pipeline Insight, 2025 - Product Thumbnail Image

Cerebral Amyloid Angiopathy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Peripheral Nerve Injuries - Pipeline Insight, 2025 - Product Thumbnail Image

Peripheral Nerve Injuries - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Dopamine D1 Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Dopamine D1 Receptor Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Leptomeningeal Disease -Pipeline Insight, 2025 - Product Thumbnail Image

Leptomeningeal Disease -Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Cannabinoid Receptor CB1 Inverse Agonists - Pipeline Insight, 2025 - Product Thumbnail Image

Cannabinoid Receptor CB1 Inverse Agonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Autistic Disorder- Pipeline Insight, 2025 - Product Thumbnail Image

Autistic Disorder- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Spasmodic-torticollis - Pipeline Insight, 2025 - Product Thumbnail Image

Spasmodic-torticollis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
LRRK2 Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

LRRK2 Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
MELAS Sundrome - Pipeline Insight, 2025 - Product Thumbnail Image

MELAS Sundrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
GABA A Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

GABA A Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Dopamine D2 Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Dopamine D2 Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Dementia with Lewy Bodies (DLB) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Dementia with Lewy Bodies (DLB) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 88 Pages
  • Global
From
From
Traumatic Brain Injury - Epidemiology Forecast - 2034 - Product Thumbnail Image

Traumatic Brain Injury - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 60 Pages
  • Global
From
From
From
West Syndrome - Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

West Syndrome - Market Insight, Epidemiology and Market Forecast - 2034

  • Drug Pipelines
  • June 2024
  • 200 Pages
  • Global
From
From
NE-3107 Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

NE-3107 Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • March 2024
  • 30 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more